SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-013281
Filing Date
2023-02-21
Accepted
2023-02-21 16:06:24
Documents
13
Period of Report
2023-02-21
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea174041-8k_immucell.htm   iXBRL 8-K 27826
2 PRESS RELEASE OF IMMUCELL CORPORATION DATED FEBRUARY 21, 2023 ea174041ex99-1_immucell.htm EX-99.1 51015
  Complete submission text file 0001213900-23-013281.txt   261499

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE iccc-20230221.xsd EX-101.SCH 3227
4 XBRL LABEL FILE iccc-20230221_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE iccc-20230221_pre.xml EX-101.PRE 22359
7 EXTRACTED XBRL INSTANCE DOCUMENT ea174041-8k_immucell_htm.xml XML 3482
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

IRS No.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 23648093
SIC: 2835 In Vitro & In Vivo Diagnostic Substances